Lymphoma / Leukemia / Myeloma News From Medical News Today
Thu, 11 Mar 2010 01:20:44 +0100
2010 Recipient Of Minority Scholar Award Will Conduct Clinical Research On Leukemia
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year...
Wed, 10 Mar 2010 08:00:00 PST
Infectious Virus Hidden In Chromosomes During Latency Can Be Passed From Parents To Children
Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life...
Tue, 09 Mar 2010 04:00:00 PST
Key Cause Of Chronic Leukemia Progression Identified By Study
Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J...
Mon, 08 Mar 2010 00:00:00 PST
NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia...
Thu, 04 Mar 2010 20:00:00 PST
NICE Appraisal Of Azacitidine For Myelodysplastic Syndromes
The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of azacitidine (Vidaza, Celgene) for myelodysplastic syndromes...
Thu, 04 Mar 2010 18:00:00 PST
Targeting Leukaemia Cell's Gene 'addiction' Presents New Strategy For Treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing...
Thu, 04 Mar 2010 04:00:00 PST
FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010...
Wed, 03 Mar 2010 05:00:00 PST
ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S...
Wed, 03 Mar 2010 02:00:00 PST
U.S. Food And Drug Administration (FDA) Sets 22 March For Oncologic Drugs Advisory Committee (ODAC) Meeting To Review OMAPRO™
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010...
Wed, 03 Mar 2010 01:00:00 PST
Over-Expression Of Gene Regulator Spurs Development Of Leukemia In Babies With Down Syndrome
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets...
Wed, 03 Mar 2010 00:00:00 PST
|
